[ad_1]
InMedica’s bonds are offered to private and institutional investors who receive an annual interest rate of 5%. The issue is being launched to refinance the previous issue in the amount of EUR 5 million. The remaining funds will be used to finance the acquisition of new clinics and organic development. “Even if the pandemic has brought a lot of uncertainty into the market, we see clearly growing potential in the health sector. This led to the decision to continue the ambitious expansion plans and develop new projects that require additional investments. We value investors’ trust and we are confident that by investing new funds effectively, we can create value for all stakeholders: bond investors, our shareholders and of course patients, “said KÄ™stutis Broniukaitis, CEO of InMedica. According to the CEO of InMedica has the pandemic highlighted the growing demand for medical services that are opening up new development opportunities for medical institutions. “Currently, InMedica’s focus is on improving the quality and accessibility of services to patients. Therefore, the funds are being used to develop new clinics, Buying modern equipment and recruiting the most professional specialists. This enables us to continuously grow the efficiency of our clinics and adapt successfully to changes in the market, “emphasized Mr. Broniukaitis. “This is the second bond issue from the medical clinics issuer is high. It is noteworthy that the local bond market is dominated by players from the real estate sector, which makes InMedica’s bond security an excellent tool for diversifying a bond portfolio. “In total, investors can buy up to 80,000 units of corporate bonds. The face value of a bond is 100 euros. Ab December 8ththat, 2021, the company’s public bond will be distributed by Å iaulių bankas. Distribution is scheduled to end on December 16, 2021that at 12 p.m. GMT + 2. The newly issued securities will be included in the alternative stock market First north, managed by Nasdaq Vilnius. Sorainen & Partners was selected as a certified advisor for the bonds.
About InMedica With a network of 34 clinics in several cities, InMedica is one of the largest private medical centers in Lithuania. InMedica offers diagnostic, outpatient, surgical, dental and other medical services. The InMedica group consists of 21 primary care centers, 4 broad-based cardiology clinics, 1 specialized cardiology clinic, 6 walk-in clinics and 3 laboratories. The InMedica Group has more than 1000 employees and provides health services to more than 100,000 registered patients. In 2020 the group achieved sales of 18.0 million euros. Since February 2019, 70% of the shares in InMedica have been owned by the INVL Baltic Sea Growth Fund, one of the largest private equity investment funds in the Baltic States, through its subsidiary BSGF Sanus.
About the INVL Baltic Sea Growth Fund The INVL Baltic Sea Growth Fund with a total volume of EUR 165 million is one of the largest private equity funds in the Baltic region with the European Investment Fund (EIF) as the anchor investor. The EIF, which is part of the European Investment Bank, has, with the support of the European Fund for Strategic Investments, a key element of the Investment Plan for Europe (or “Junker Plan”), raised 30 million from the Baltic Innovation Fund, the “umbrella fund” initiative which was developed in cooperation with the governments of Lithuania, Latvia and Estonia. The aim is to increase capital investments in small and medium-sized companies with high growth potential in the Baltic states. The Fund seeks to put together a diversified portfolio of companies targeting transactions with majority or significant minority interests, writing tickets of 10 to 30 million euros that have high growth potential and the ability to compete on a truly global scale. The fund focuses specifically on the Baltic states and the neighboring regions of Poland, Scandinavia and Central Europe. To date, the fund has invested in four companies in the healthcare, civil engineering and environmental management (plastics recycling and waste management) sectors. The fund is managed by one of the leading Lithuanian asset management companies, INVL Asset Management, which is part of the Invalda INVL group. The group’s companies manage pension and mutual funds, alternative investments, individual portfolios, private equity investments and other financial instruments. More than 200,000 clients in Lithuania and Latvia as well as international investors entrusted the group with assets under management of more than 1.5 billion euros at the end of 2019. Invalda INVL has been active since 1991 and can look back on a solid track record. Invalda INVL has 30 years of experience in managing private equity investments in the Baltic countries and in the CEE landscape, developing companies into industry-leading market leaders.
More information: Kęstutis Broniukaitis InMedica CEO Tel. +370 618 19174 Email: [email protected]
[ad_2]
